GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Artificial Intelligence /CADe and CRC
46

CADe and CRC

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated September 1, 2025

Computer-Aided Detection (CADe) and Colorectal Cancer (CRC) are connected through the use of artificial intelligence (AI) technologies to improve the detection of polyps during colonoscopy procedures, which is a critical step in CRC prevention. Here's an in-depth explanation based on the context provided:


What is CADe?

CADe refers to computer-aided detection systems that use AI algorithms to assist gastroenterologists during colonoscopy procedures. These systems analyze real-time images captured during the procedure to highlight potential polyps or abnormalities in the colon that could be missed by human observation alone.


Role of CADe in CRC Prevention

Colorectal cancer typically develops from precancerous polyps, such as adenomas or serrated lesions. Early detection and removal of these polyps during colonoscopy can significantly reduce the risk of developing CRC. CADe aims to enhance the detection rate of these polyps, thereby improving the effectiveness of colonoscopy as a preventive measure.


Evidence from Recent Studies

The American Gastroenterological Association (AGA) reviewed data from 41 randomized controlled trials involving over 32,000 patients to evaluate the effectiveness of CADe systems for CRC prevention. Key findings include:

  1. Increased Adenoma Detection Rate (ADR): CADe-assisted colonoscopy showed an 8% increase in ADR, which is a critical metric for assessing the quality of colonoscopy procedures. Higher ADRs are associated with reduced risks of interval colorectal cancer (cancer that develops between regular screenings).

  2. Detection of Advanced Adenomas and Serrated Lesions: CADe demonstrated modest improvements in detecting advanced adenomas and serrated lesions, which are more likely to progress to cancer.

  3. Concerns About Overdiagnosis: While CADe increases the number of polyps detected, many of these polyps are diminutive and unlikely to progress to cancer. This raises concerns about overdiagnosis, unnecessary follow-up procedures, increased costs, and resource strain.


Uncertain Long-Term Outcomes

Despite the short-term benefits in polyp detection, it remains unclear whether CADe-assisted colonoscopy leads to a reduction in colorectal cancer incidence or mortality. The available evidence is of "very low certainty," meaning that more robust, long-term studies are needed to establish whether CADe translates into fewer cancers or deaths.


Challenges and Considerations

  1. Overdiagnosis and Resource Strain: Detecting diminutive polyps that are clinically insignificant could lead to unnecessary surveillance and increased healthcare costs.

  2. Cost-Effectiveness: The financial implications of implementing CADe systems in clinical practice are still uncertain, especially given the modest improvements in detection rates.

  3. Patient-Centered Outcomes: The impact of CADe on patient satisfaction, anxiety, and overall experience during colonoscopy has not been thoroughly studied.

  4. Implementation Variability: Some centers already use CADe systems like GI Genius, but adoption varies widely across healthcare settings.


Future Directions

The AGA highlights the need for:

  1. Better Long-Term Data: Studies focusing on interval cancer reduction, cost-effectiveness, and patient-centered outcomes are essential to determine the true value of CADe in CRC prevention.

  2. Improved Software: Future iterations of CADe systems, trained on larger datasets and optimized for detecting clinically significant polyps, may enhance performance and address current limitations.

  3. Dynamic Evidence-Based Practice: The AGA plans to revisit its recommendations as more robust evidence emerges, underscoring the importance of balancing innovation with proven clinical benefits.


Current Status of CADe in CRC Prevention

At present, CADe is considered a promising but unproven tool in the fight against colorectal cancer. While it shows potential for improving polyp detection rates, its impact on long-term outcomes like cancer incidence and mortality remains uncertain. Healthcare providers and researchers must continue to evaluate its effectiveness while striving to optimize its use in clinical practice.

Related Q&A

47

AI-Based Computer-Aided Detection in Colonoscopy

AI-based computer-aided detection (CADe) in colonoscopy refers to the use of artificial intelligence (AI) systems to assist healthcare professionals in identifying abnormalities, such as polyps or adenomas, in...

01

AI in Medical Publishing: Assistance Is Acceptable, Authorship Is Human: BMJ Future Health | August 2026

Introduction: Generative AI is rapidly entering medical writing, research, clinical documentation, and evidence synthesis. The central question is no longer whether researchers will use AI, but where its...

02

Translating Artificial Intelligence in Pathology into Real Clinical Practice: NEJM AI | August 2026

Introduction: Artificial intelligence (AI) has demonstrated remarkable ability to extract diagnostic, prognostic, and molecular information from routine hematoxylin and eosin (H&E)-stained pathology slides. Despite this rapid scientific progress,...

03

Machine Learning Outperforms AIMS65 and Glasgow-Blatchford Score for Mortality Prediction in GI Bleeding: Adv GastroHep | August 2026

Gastrointestinal bleeding (GIB) is a common medical emergency associated with significant morbidity and mortality. Early identification of high-risk patients is critical for decisions regarding hospitalization, intensive care, urgent...

04

AI-Powered Histology Predicts the Best Adjuvant Chemotherapy for Resected Pancreatic Cancer (PANCprAId): JCO | August 2026

Introduction: Following curative surgery for pancreatic ductal adenocarcinoma (PDAC), modified FOLFIRINOX (mFOLFIRINOX) has become the preferred adjuvant chemotherapy for fit patients, while gemcitabine (GEM) remains an option for...

05

AI-Triggered Rapid Response Teams: NEJM AI | July 2026

Introduction: Early recognition of clinical deterioration remains a major challenge in hospitalized patients. This multicenter study evaluated whether combining the Epic Deterioration Index (EDI), a real-time machine-learning prediction...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer